Decision Aid (DA) for Renal Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Decision Aid (DA) Web Tool, Institutional Pamphlet.
- Who it may be relevant to
- Registry conditions: Kidney Tumor, Renal Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of a Decision Aid in the Treatment Planning of Small Renal Tumors
Overview
The objective of this study is to understand how patients make decisions about treating their kidney masses, and to identify key values and preferences for treating their kidney masses. The study team will develop a decision aid (DA) using the decision-analytic model to communicate personalized benefit/harm estimates to patients and promote patient-centered treatment of renal tumors.
Interventions
- Other Decision Aid (DA) Web Tool
The DA web tool provides information on kidney masses and available treatment options. It uses risk communication, directed teaching, and interactive benefit-harm assessment to present information. - Other Institutional Pamphlet
The institutional pamphlet provides information on kidney masses, but does not use risk communication, directed teaching, or interactive benefit-harm assessment.
Primary outcome measures
- Knowledge Score [Time frame: Pre-Counsel, 1 day Visit]
- Decision Satisfaction Score [Time frame: Post-Counsel, 1 day Visit]
- Shared Decision Making [Time frame: Post-Counsel, 1 day Visit]
Eligibility criteria
Inclusion criteria
- Male and female post-op and pre-op patients, ages 18 and older, diagnosed with a localized renal tumor up to 4 cm in diameter.
- Patients scheduled for standard-of-care clinical exams with the NYU Urology Department
Exclusion criteria
- Stage IV cancer of any type
- Inability to provide informed consent
- Vulnerable subjects will not be recruited
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Health services research
Study locations
United States · 1 center
- NYU Langone Health — New York
Publications
- Fogarty J, Siriruchatanon M, Makarov D, Langford A, Kang S. An Evaluation of a Web-Based Decision Aid for Treatment Planning of Small Kidney Tumors: Pilot Randomized Controlled Trial. JMIR Res Protoc. 2022 Sep 2;11(9):e41451. doi: 10.2196/41451. PMID 36053558
Identifiers
NCT: NCT05387863 · 21-01670